2022
EPCO-40. INFRATENTORIAL NF2 MUTANT SPORADIC MENINGIOMAS DIFFER FROM THOSE IN SUPRATENTORIAL LOCATIONS AND ARE MORE BENIGN
Vasandani S, Vetsa S, Jalal M, Yalcin K, Marianayagam N, Nadar A, Jin L, Fulbright R, Erson-Omay E, Günel M, Moliterno J. EPCO-40. INFRATENTORIAL NF2 MUTANT SPORADIC MENINGIOMAS DIFFER FROM THOSE IN SUPRATENTORIAL LOCATIONS AND ARE MORE BENIGN. Neuro-Oncology 2022, 24: vii125-vii125. DOI: 10.1093/neuonc/noac209.474.Peer-Reviewed Original ResearchSupratentorial locationWhole-exome sequencing dataHigh-risk clinical featuresLonger progression-free survivalProgression-free survivalExtent of resectionShorter overall survivalDifferent intracranial locationsChromosome 1p deletionOverall survivalClinical featuresInfratentorial tumorsAggressive featuresClinical manifestationsClinical behaviorKi-67Intracranial locationMeningiomasTumorsUnstable tumorsNF2 lossResectionGenomic profilesPatientsExome sequencing data
2020
Clinical and genomic factors associated with seizures in meningiomas.
Gupte TP, Li C, Jin L, Yalcin K, Youngblood MW, Miyagishima DF, Mishra-Gorur K, Zhao AY, Antonios J, Huttner A, McGuone D, Blondin NA, Contessa JN, Zhang Y, Fulbright RK, Gunel M, Erson-Omay Z, Moliterno J. Clinical and genomic factors associated with seizures in meningiomas. Journal Of Neurosurgery 2020, 135: 835-844. PMID: 33276341, DOI: 10.3171/2020.7.jns201042.Peer-Reviewed Original ResearchPreoperative seizuresPostoperative seizuresAtypical histologyMultivariate analysisWorse progression-free survivalGenomic subgroupsYale-New Haven HospitalAssociation of seizuresAntiepileptic drug useProgression-free survivalSeizure-free patientsGross total resectionExtent of resectionMultiple risk factorsNF2 mutationsNew Haven HospitalLogistic regression modelsPostoperative radiationSeizure freedomClinical courseSeizure presentationSomatic NF2 mutationsBrain invasionRecurrent tumorsRisk factorsAssociations of meningioma molecular subgroup and tumor recurrence
Youngblood MW, Miyagishima DF, Jin L, Gupte T, Li C, Duran D, Montejo JD, Zhao A, Sheth A, Tyrtova E, Özduman K, Iacoangeli F, Peyre M, Boetto J, Pease M, Avşar T, Huttner A, Bilguvar K, Kilic T, Pamir MN, Amankulor N, Kalamarides M, Erson-Omay EZ, Günel M, Moliterno J. Associations of meningioma molecular subgroup and tumor recurrence. Neuro-Oncology 2020, 23: 783-794. PMID: 33068421, PMCID: PMC8099468, DOI: 10.1093/neuonc/noaa226.Peer-Reviewed Original ResearchConceptsDivergent clinical coursesMolecular subgroupsClinical courseClinical outcomesProgression-free survivalExtent of resectionKaplan-Meier analysisLong-term outcomesLow-grade tumorsCox proportional hazardsDistinct clinical outcomesPostoperative radiationIndependent predictorsMale sexRecurrence rateSurveillance imagingTumor recurrencePrevious recurrencesClinical prognosticationKi-67Outcome dataAggressive subgroupRecurrenceElevated recurrenceProportional hazards
2019
GENE-56. MENINGIOMA GENOMIC SUBGROUP AS A PREDICTOR OF POST-OPERATIVE PATIENT OUTCOMES: IMPLICATIONS FOR TREATMENT AND FOLLOW-UP
Youngblood M, Sheth A, Zhao A, Montejo J, Duran D, Li C, Tyrtova E, Özduman K, Peyre M, Boetto J, Omay S, Kalamarides M, Erson-Omay E, Günel M, Moliterno J. GENE-56. MENINGIOMA GENOMIC SUBGROUP AS A PREDICTOR OF POST-OPERATIVE PATIENT OUTCOMES: IMPLICATIONS FOR TREATMENT AND FOLLOW-UP. Neuro-Oncology 2019, 21: vi109-vi110. PMCID: PMC6846980, DOI: 10.1093/neuonc/noz175.458.Peer-Reviewed Original ResearchExtent of resectionPost-operative radiationRecurrence-free survivalPatient outcomesFree survivalGenomic subgroupsAverage recurrence-free survivalRetrospective chart reviewPost-operative yearPI3KPatient outcome dataPost-operative patient outcomesCox proportional hazardsCritical neurovascular structures